Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 13

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Multiple sclerosis

Recruiting

Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Aciclovir sodium
  • Sponsor:Region Uppsala

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A Study of IMVT-1402 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy to Prevent Disease Relapse

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Ischaemic stroke

Recruiting

A study testing tenecteplase given directly into the artery after blood clot removal in patients with acute ischemic stroke in the front part of the brain

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Ischaemic stroke

Recruiting

Study of cangrelor and acetylsalicylic acid in patients with ischemic stroke requiring emergency carotid artery stenting and mechanical thrombectomy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Medical University Of Graz

Fabry's disease

Recruiting

Title: Evaluating low-dose prednisone with standard therapy to improve heart function in patients with cardiac manifestations of Fabry disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Medical University Of Lodz

Dementia Alzheimer's type

Recruiting

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for treating agitation in Alzheimer's disease patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Spinal muscular atrophy

Recruiting

Study of Apitegromab Treatment in Children Under 2 Years Old with Spinal Muscular Atrophy (SMA)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

PIK3CA related overgrowth spectrum

Recruiting

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Partial seizures

Recruiting

Study of Probenecid for Controlling Cluster Seizures in Patients with Focal Epilepsy During Pre-surgical Video-EEG Monitoring

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Probenecid
  • Sponsor:Fondation A De Rothschild

Muscle spasticity

Recruiting

Comparison of Pregabalin and Baclofen Treatment in Patients with Spastic Motor Behavior Following Cervical or Thoracic Spinal Cord Injury

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Baclofen
  • Sponsor:Fakultni Nemocnice V Motole

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.